Zhang Xu, Liu Pan, Fu Qiang, Luo Qian-Kun, Yu Peng-Fei, Chen Jing-Yu, Wang Yu-Zhu, Qin Tao
Department of Hepato-Biliary-Pancreatic Surgery, Henan Provincial People's Hospital, Zhengzhou, Henan 450003, P.R. China.
Exp Ther Med. 2024 Jul 5;28(3):352. doi: 10.3892/etm.2024.12642. eCollection 2024 Sep.
Hepatocellular carcinoma (HCC) is one of the most aggressive types of cancer. Although it has a high mortality rate, there is currently no effective treatment for HCC. Lenvatinib has traditionally been used as the first-line treatment for advanced HCC (aHCC); however, resistance to this therapy is common. It can be difficult to select effective second-line drugs to overcome lenvatinib resistance when treating aHCC. For patients with aHCC, poor treatment efficacy can result in patients missing the optimal treatment window and can lead to an irreversible situation. Lenalidomide has begun to be used to treat HCC; however, to the best of our knowledge, its efficacy in patients with lenvatinib-resistant HCC remains to be reported on in the literature. The present case report, to the best of our knowledge, describes the first case in the literature of a patient with lenvatinib-resistant aHCC who achieved a partial response after the treatment regimen was switched to lenalidomide. The present case report provides a promising novel route for the treatment of lenvatinib-resistant HCC.
肝细胞癌（HCC）是最具侵袭性的癌症类型之一。尽管其死亡率很高，但目前尚无针对HCC的有效治疗方法。乐伐替尼传统上一直被用作晚期HCC（aHCC）的一线治疗药物；然而，对这种疗法产生耐药性很常见。在治疗aHCC时，选择有效的二线药物来克服乐伐替尼耐药性可能会很困难。对于aHCC患者，治疗效果不佳可能导致患者错过最佳治疗窗口期，并可能导致不可逆转的局面。来那度胺已开始用于治疗HCC；然而，据我们所知，其在乐伐替尼耐药HCC患者中的疗效仍有待文献报道。据我们所知，本病例报告描述了文献中首例乐伐替尼耐药aHCC患者在治疗方案改用为来那度胺后获得部分缓解的病例。本病例报告为乐伐替尼耐药HCC的治疗提供了一条有前景且新颖的途径。
